Riskpilot← Back to searchSign inGet full accessBreye Therapeutics ApS
APSActiveCVR 40279865Agern Alle 24Manufacture of pharmaceutical preparations · NACE 2120Est. 20193 employees
Revenue 2025
DKK -7,5M
-3% vs 2024
EBITDA margin
1089.9%
-10% vs 2024
Equity ratio
-71.2%
Financial strength
Net profit 2025
DKK -89,1M
-27% vs 2024
| Revenue | DKK -7,5M | -3% |
| EBITDA | DKK -82,2M | -10% |
| Net profit | DKK -89,1M | -27% |
| Total assets | DKK 57M | -6% |
| Equity | DKK -40,6M | -184% |
| Employees | 3 | — |
Legal name
Breye Therapeutics ApS
CVR number
40279865
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
13. februar 2019
Share capital
DKK 341.672
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse
Company purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Address
Agern Alle 24
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 356 | -68 | -674 | -2.883 | -7.812 | -7.546 |
| Staff expenses | -0 | -247 | -64 | -1.717 | -6.407 | -7.080 |
| EBITDA | 356 | -315 | -738 | -19.836 | -74.961 | -82.242 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -411 | -397 |
| EBIT | 356 | -315 | -738 | -19.836 | -75.372 | -82.639 |
| Net financials | -13 | -28 | -42 | -941 | -273 | -12.001 |
| Profit before tax | 343 | -342 | -780 | -20.777 | -75.646 | -94.640 |
| Tax | 79 | -53 | -0 | -6.202 | -5.496 | -5.500 |
| Net profit | 264 | -290 | -780 | -14.575 | -70.150 | -89.140 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 474 | 14.174 | 18.746 | 24.815 | 60.682 | 57.048 |
| Equity | 314 | 28 | -752 | 14.526 | 48.485 | -40.638 |
| Long-term debt | 0 | 13.814 | 18.478 | 7.101 | 3.767 | 1.944 |
| Short-term debt | 106 | 332 | 1.020 | 3.188 | 8.430 | 95.741 |
| Total debt | 106 | 14.146 | 19.498 | 10.289 | 12.196 | 97.685 |
EBITDA margin
-8224220000.0%
This company
15.8%
Market median
-52052025416% vs market
20202025
Equity ratio
-71.2%
This company
38.2%
Market median
-286% vs market
20202025
Return on equity
-8913984600.0%
This company
18.4%
Market median
-48445568578% vs market
20202025
Net profit margin
-8913984600.0%
This company
8.1%
Market median
-110049192693% vs market
20202025
Asset turnover
-0.13×
This company
1.12×
Market median
-112% vs market
20202025
Debt / equity
2.40×
This company
0.62×
Market median
-287% vs market
20202025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via CVR / Virk · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via CVR / Virk · Period 2019-02-13 – 2020-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
UM Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 33.3% | 33.3% | 2024 |
| Individual | 20.0% | 20.0% | 2023 | |
Visus Holding ApS | Company | 10.0% | 10.0% | 2024 |
BII Holdings A/S | Company | 5.0% | 5.0% | 2023 |
| Individual | 5.0% | 5.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2020 | |
BioInnovation Institute Fonden | Company | 10.0% | 10.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Breye Therapeutics ApS Board members of Breye Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulrik Mouritzen | Chief Executive Officer | 0 companies |
| Jørgen Søberg Petersen | Board of Directors | 0 companies |
| Gabriela Burian | Board of Directors | 0 companies |
| Chiara Rossana Maria Liberati | Board of Directors | 0 companies |
| Jimmy Arnold V Van Heusden | Chairman | 0 companies |
| Carl Johan Kördel | Board of Directors | 0 companies |